Literature DB >> 21527534

Salt bridges overlapping the gonadotropin-releasing hormone receptor agonist binding site reveal a coincidence detector for G protein-coupled receptor activation.

Jo Ann Janovick1, Irina D Pogozheva, Henry I Mosberg, P Michael Conn.   

Abstract

G protein-coupled receptors (GPCRs) play central roles in most physiological functions, and mutations in them cause heritable diseases. Whereas crystal structures provide details about the structure of GPCRs, there is little information that identifies structural features that permit receptors to pass the cellular quality control system or are involved in transition from the ground state to the ligand-activated state. The gonadotropin-releasing hormone receptor (GnRHR), because of its small size among GPCRs, is amenable to molecular biological approaches and to computer modeling. These techniques and interspecies comparisons are used to identify structural features that are important for both intracellular trafficking and GnRHR activation yet distinguish between these processes. Our model features two salt (Arg(38)-Asp(98) and Glu(90)-Lys(121)) and two disulfide (Cys(14)-Cys(200) and Cys(114)-Cys(196)) bridges, all of which are required for the human GnRHR to traffic to the plasma membrane. This study reveals that both constitutive and ligand-induced activation are associated with a "coincidence detector" that occurs when an agonist binds. The observed constitutive activation of receptors lacking Glu(90)-Lys(121), but not Arg(38)-Asp(98) ionic bridge, suggests that the role of the former connection is holding the receptor in the inactive conformation. Both the aromatic ring and hydroxyl group of Tyr(284) and the hydrogen bonding of Ser(217) are important for efficient receptor activation. Our modeling results, supported by the observed influence of Lys(191) from extracellular loop 2 (EL2) and a four-residue motif surrounding this loop on ligand binding and receptor activation, suggest that the positioning of EL2 within the seven-α-helical bundle regulates receptor stability, proper trafficking, and function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21527534      PMCID: PMC3141895          DOI: 10.1124/jpet.111.180869

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease.

Authors:  Alfredo Ulloa-Aguirre; Jo Ann Janovick; Shaun P Brothers; P Michael Conn
Journal:  Traffic       Date:  2004-11       Impact factor: 6.215

2.  An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation.

Authors:  J V Cook; K A Eidne
Journal:  Endocrinology       Date:  1997-07       Impact factor: 4.736

3.  Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints.

Authors:  P Güntert; K Wüthrich
Journal:  J Biomol NMR       Date:  1991-11       Impact factor: 2.835

Review 4.  G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization.

Authors:  R J Lefkowitz
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

Review 5.  Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor.

Authors:  S C Sealfon; H Weinstein; R P Millar
Journal:  Endocr Rev       Date:  1997-04       Impact factor: 19.871

6.  Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor.

Authors:  Jo Ann Janovick; Mark Goulet; Eugene Bush; Jonathan Greer; David G Wettlaufer; P Michael Conn
Journal:  J Pharmacol Exp Ther       Date:  2003-02-11       Impact factor: 4.030

7.  A locus of the gonadotropin-releasing hormone receptor that differentiates agonist and antagonist binding sites.

Authors:  W Zhou; V Rodic; S Kitanovic; C A Flanagan; L Chi; H Weinstein; S Maayani; R P Millar; S C Sealfon
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

8.  Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans.

Authors:  Alfredo Leaños-Miranda; Alfredo Ulloa-Aguirre; Tae H Ji; Jo Ann Janovick; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

9.  Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect.

Authors:  Shaun P Brothers; Anda Cornea; Jo Ann Janovick; P Michael Conn
Journal:  Mol Endocrinol       Date:  2004-04-22

10.  Evolved regulation of gonadotropin-releasing hormone receptor cell surface expression.

Authors:  Jo Ann Janovick; Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

View more
  9 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

2.  Rescue of misrouted GnRHR mutants reveals its constitutive activity.

Authors:  Jo Ann Janovick; Irina D Pogozheva; Henry I Mosberg; Anda Cornea; P Michael Conn
Journal:  Mol Endocrinol       Date:  2012-05-17

Review 3.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

4.  Structural mechanisms of constitutive activation in the C5a receptors with mutations in the extracellular loops: molecular modeling study.

Authors:  Gregory V Nikiforovich; Thomas J Baranski
Journal:  Proteins       Date:  2011-09-30

5.  Species sequence differences determine the interaction of GnRH receptor with the cellular quality control system.

Authors:  Alejandro Cabrera-Wrooman; Jo Ann Janovick; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-07-24       Impact factor: 4.102

6.  A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.

Authors:  P Michael Conn; Emery Smith; Timothy Spicer; Peter Chase; Louis Scampavia; Jo Ann Janovick
Journal:  Assay Drug Dev Technol       Date:  2014-05       Impact factor: 1.738

Review 7.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Authors:  P Michael Conn; David C Smithson; Peter S Hodder; M David Stewart; Richard R Behringer; Emery Smith; Alfredo Ulloa-Aguirre; Jo Ann Janovick
Journal:  Pharmacol Res       Date:  2013-12-25       Impact factor: 7.658

Review 8.  Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding.

Authors:  Colleen A Flanagan; Ashmeetha Manilall
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-24       Impact factor: 5.555

9.  Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.

Authors:  Jo Ann Janovick; Timothy P Spicer; Thomas D Bannister; Louis Scampavia; P Michael Conn
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.